249 related articles for article (PubMed ID: 17938252)
1. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
Schulz H; Rehwald U; Morschhauser F; Elter T; Driessen C; Rüdiger T; Borchmann P; Schnell R; Diehl V; Engert A; Reiser M
Blood; 2008 Jan; 111(1):109-11. PubMed ID: 17938252
[TBL] [Abstract][Full Text] [Related]
2. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.
Advani RH; Horning SJ; Hoppe RT; Daadi S; Allen J; Natkunam Y; Bartlett NL
J Clin Oncol; 2014 Mar; 32(9):912-8. PubMed ID: 24516013
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.
Eichenauer DA; Fuchs M; Pluetschow A; Klimm B; Halbsguth T; Böll B; von Tresckow B; Nogová L; Borchmann P; Engert A
Blood; 2011 Oct; 118(16):4363-5. PubMed ID: 21828141
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group.
Rehwald U; Schulz H; Reiser M; Sieber M; Staak JO; Morschhauser F; Driessen C; Rudiger T; Muller-Hermelink K; Diehl V; Engert A;
Blood; 2003 Jan; 101(2):420-4. PubMed ID: 12509381
[TBL] [Abstract][Full Text] [Related]
5. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment?
Fanale M
Hematology Am Soc Hematol Educ Program; 2013; 2013():406-13. PubMed ID: 24319212
[TBL] [Abstract][Full Text] [Related]
6. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
Pijuan L; Vicioso L; Bellosillo B; Ferrer MD; Baró T; Pedro C; Lloreta-Trull J; Munné A; Serrano S
Am J Surg Pathol; 2005 Oct; 29(10):1399-403. PubMed ID: 16160485
[TBL] [Abstract][Full Text] [Related]
7. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Schröder L; Fuchs M; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
Blood; 2018 Oct; 132(14):1519-1525. PubMed ID: 30064977
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.
Ekstrand BC; Lucas JB; Horwitz SM; Fan Z; Breslin S; Hoppe RT; Natkunam Y; Bartlett NL; Horning SJ
Blood; 2003 Jun; 101(11):4285-9. PubMed ID: 12586628
[TBL] [Abstract][Full Text] [Related]
9. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
Maeda LS; Advani RH
Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
[TBL] [Abstract][Full Text] [Related]
10. Nodular lymphocyte-predominant Hodgkin lymphoma.
Fuchs M; Eichenauer DA; Nogová L; Diehl V; Engert A;
Curr Hematol Malig Rep; 2008 Jul; 3(3):126-31. PubMed ID: 20425457
[TBL] [Abstract][Full Text] [Related]
11. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center.
Menke JR; Spinner MA; Natkunam Y; Warnke RA; Advani RH; Gratzinger DA
Arch Pathol Lab Med; 2021 Jun; 145(6):753-758. PubMed ID: 32991677
[TBL] [Abstract][Full Text] [Related]
12. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
van Grotel M; Lam KH; de Man R; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM
Leuk Lymphoma; 2006 Aug; 47(8):1504-10. PubMed ID: 16966260
[TBL] [Abstract][Full Text] [Related]
13. How I treat nodular lymphocyte predominant Hodgkin lymphoma.
Advani RH; Hoppe RT
Blood; 2013 Dec; 122(26):4182-8. PubMed ID: 24215035
[TBL] [Abstract][Full Text] [Related]
14. Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab.
Unal A; Sari I; Deniz K; Ozkan M; Kontas O; Eser B; Cetin M
Leuk Lymphoma; 2005 Nov; 46(11):1613-7. PubMed ID: 16236615
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma.
Akhtar S; Elhassan TAM; Edesa W; Rauf MS; Zahir MN; Maghfoor I
Ann Hematol; 2016 Jan; 95(1):49-54. PubMed ID: 26467917
[TBL] [Abstract][Full Text] [Related]
16. The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma.
Hartmann S; Plütschow A; Mottok A; Bernd HW; Feller AC; Ott G; Cogliatti S; Fend F; Quintanilla-Martinez L; Stein H; Klapper W; Möller P; Rosenwald A; Engert A; Hansmann ML; Eichenauer DA
Am J Hematol; 2019 Nov; 94(11):1208-1213. PubMed ID: 31396979
[TBL] [Abstract][Full Text] [Related]
17. Nodular lymphocyte-predominant hodgkin lymphoma with atypical T cells: a morphologic variant mimicking peripheral T-cell lymphoma.
Sohani AR; Jaffe ES; Harris NL; Ferry JA; Pittaluga S; Hasserjian RP
Am J Surg Pathol; 2011 Nov; 35(11):1666-78. PubMed ID: 21997687
[TBL] [Abstract][Full Text] [Related]
18. [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma].
Liu YH; Zhuang HG; Lin HL; Wu QL; Luo DL; Li L; Luo XL
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):594-8. PubMed ID: 17243292
[TBL] [Abstract][Full Text] [Related]
19. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.
Akhtar S; Montoto S; Boumendil A; Finel H; Masszi T; Jindra P; Nemet D; Fuhrmann S; Beguin Y; Castagna L; Ferrara F; Capria S; Malladi R; Moraleda JM; Bloor A; Ghesquières H; Meissner J; Sureda A; Dreger P
Am J Hematol; 2018 Jan; 93(1):40-46. PubMed ID: 28971503
[TBL] [Abstract][Full Text] [Related]
20. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
